Yoann P.
- Country
- France
- Department
- Oncology-Radiotherapy
Research Overview
- Efficacy of LY3537021 plus combination therapy versus placebo for chemotherapy-induced nausea and vomiting in adults with malignant disease
- Phase 3 Randomized, Double-blind, Placebo-controlled Study of Apalutamide and GnRH Agonist in High-risk Localized or Locally Advanced Prostate Cancer with Primary Radiation Therapy
- Phase III Study on Laryngeal Preservation in Locally Advanced Squamous Cell Carcinomas of the Larynx or Hypopharynx: Comparing Induction Chemotherapy with Cisplatin, 5-Fluorouracil, and Docetaxel Followed by Radiotherapy Versus Concomitant Radiotherapy with Cisplatin.
Data & Insights
Has run more than one trial at 165 of 323 partner sites.
Specializations
Thoracic and Head and Neck Oncology
Clinical activity centers on non-small cell lung cancer, small cell lung cancer, pleural mesothelioma, and head and neck squamous cell carcinoma, with additional interest in locally advanced and metastatic disease. The investigator is also involved in radiotherapy-based treatment strategies and combined-modality approaches for resected and unresectable tumors.
- Non-small cell lung cancer
- Small cell lung cancer
- Head and neck squamous cell carcinoma
- Pleural mesothelioma
Therapeutic focus includes immunotherapy, targeted therapy, and treatment intensification in advanced solid tumors.
Breast, Prostate, and Genitourinary Cancers
Research involvement spans breast cancer across early, locally advanced, and metastatic settings, including HER2-positive, HER2-low, hormone receptor-positive, and triple-negative breast cancer. The investigator also works in prostate cancer and urothelial carcinoma, reflecting a strong focus on hormonally driven and metastatic genitourinary malignancies.
- Breast cancer
- Prostate cancer
- Urothelial carcinoma
- Renal cell carcinoma
Key therapeutic areas include endocrine therapy, androgen receptor pathway targeting, and systemic regimens for advanced disease.
Hematology and Onco-Hematology
The investigator is active in acute myeloid leukemia, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, multiple myeloma, and myelodysplastic syndromes. This domain also includes aggressive and relapsed or refractory lymphoid and myeloid malignancies.
- Acute myeloid leukemia
- Chronic lymphocytic leukemia
- Lymphoma
- Myelodysplastic syndromes
- Multiple myeloma
Therapeutic interest extends to cellular therapy, bispecific antibodies, and novel combinations for relapsed or refractory blood cancers.
Autoimmune, Inflammatory, and Rare Immune-Mediated Diseases
Clinical research includes rheumatoid arthritis, systemic lupus erythematosus, giant cell arteritis, polymyalgia rheumatica, Sjögren’s syndrome, vasculitis, and systemic sclerosis. The investigator is also involved in atopic dermatitis, hidradenitis suppurativa, psoriasis, and vitiligo.
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Vasculitis
- Systemic sclerosis
- Dermatologic inflammatory disease
Therapeutic emphasis is placed on immune modulation, biologic therapy, and symptom control in chronic inflammatory disorders.
Respiratory, Critical Care, and Supportive Medicine
Additional research interests cover sepsis, septic shock, acute respiratory failure, respiratory tract infection, chronic pulmonary aspergillosis, and chronic obstructive pulmonary disease. The investigator also contributes to studies in thrombosis prevention, renal disease, and other supportive care settings linked to oncology and acute medicine.
- Sepsis and septic shock
- Acute respiratory failure
- Chronic pulmonary aspergillosis
- Thrombosis prevention
Therapeutic activity includes management of infectious complications, organ support, and treatment-related adverse effects in complex hospitalized patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.